Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150‑200 million to advance its AI‑enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next‑generation gene therapies.
Contents
IPO Milestone
| Item | Detail |
|---|---|
| Company | Exegenesis Bio Inc. |
| Filing Venue | Hong Kong Stock Exchange (HKEX) |
| Filing Date | 08 Jan 2026 |
| Founded | 2019 |
| Headquarters | Hangzhou, China |
| Estimated IPO Proceeds | USD 150‑200 million |
| Use of Proceeds | 60 % for clinical trials, 25 % for platform expansion, 15 % for working capital |
| Lead Underwriters | Goldman Sachs, J.P. Morgan, CICC (estimated) |
Technology Platforms
AAVarta – AI-Assisted AAV Capsid Evolution
- Function: Proprietary AAV capsid discovery platform using machine learning to engineer novel serotypes with enhanced tissue tropism and reduced immunogenicity
- Innovation: In silico prediction of capsid variants followed by high‑throughput in vivo screening; reduces discovery timeline from 36 months to 12 months
SODA – Silencing Oligonucleotide Design Approach
- Function: AI‑driven design of antisense oligonucleotides (ASOs) and siRNAs for target knockdown
- Advantage: Optimizes chemical modifications, delivery vectors, and off‑target profiling simultaneously
Clinical Pipeline
| Candidate | Technology | Indication | Stage | Key Differentiation |
|---|---|---|---|---|
| EXG001-307 | AAV‑based gene therapy | SMA Type 1 | Pre‑IND / IND‑enabling | Potential best‑in‑class vs. Zolgensma; lower vector dose, reduced liver toxicity |
| EXG102-031 | AAV‑based gene therapy | wAMD (wet age‑related macular degeneration) | Preclinical | Single‑ injection vs. monthly anti‑VEGF injections; sustained efficacy |
| EXG202 | AAV‑based gene therapy | Ocular neovascular diseases (wAMD, DME, RVO) | Discovery | Pan‑ocular platform targeting multiple retinal indications |
| 7 Additional Assets | Gene therapy / oligonucleotide | Various oncology/rare diseases | Discovery / Preclinical | Diversified pipeline leveraging dual platforms |
Market Opportunity
| Indication | Global Market Size (2026E) | Target Population | Competitive Landscape |
|---|---|---|---|
| SMA Type 1 | $2.8 billion | ~1,200 new cases/year (US/EU/China) | Novartis Zolgensma ($2.1M/dose), Roche Evrysdi (oral) |
| wAMD | $11.6 billion | 20 million patients globally | Regenxbio, Adverum (gene therapy); Eylea, Lucentis (anti‑VEGF) |
| DME / RVO | $7.2 billion | 10 million+ patients | Same anti‑VEGF competitors; no approved gene therapies |
Financial & Strategic Positioning
- Valuation: Pre‑money estimated at USD 500‑600 million based on comparable AI‑gene therapy companies
- Revenue Model: Near‑term partnership revenues (platform licensing); long‑term product sales and milestones
- Investor Base: Viva Biotech (incubator) remains largest shareholder; new investors include Hong Kong‑based family offices and biotech crossover funds
- Manufacturing: In‑house GMP facility in Hangzhou (2,000L scale) for AAV production; capacity for clinical supply through Phase II
Competitive Advantages
- AAVarta Platform: Novel capsids show 5‑fold higher retinal transduction and 3‑fold lower liver sequestration vs. AAV2/AAV8 in preclinical models
- Integrated AI: SODA platform reduces oligonucleotide design cycles from 6 months to 8 weeks
- Cost Efficiency: In‑house manufacturing reduces COGS by 40% vs. CDMO model
- Diversification: Dual platform (gene therapy + oligonucleotide) mitigates AAV immunogenicity risks
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Exegenesis Bio’s IPO timeline, valuation, and pipeline advancement. Actual results may differ due to market conditions, regulatory review timelines, and competitive dynamics in gene therapy.-Fineline Info & Tech
